Nuvation Bio (NUVB) Stock
Clinical stage biotech developing targeted cancer treatments. Here's the price, business snapshot, and what's worth knowing about Nuvation Bio in October 2026.
Nuvation Bio Inc (NUVB) is a clinical‑stage biopharmaceutical company focused on developing targeted oncology treatments. With a market capitalisation of about $1.45 billion, the company’s value is driven by progress across its pipeline, clinical trial readouts and regulatory milestones rather than steady revenue. Investors should note that clinical‑stage biotechs often face binary outcomes — trial successes can meaningfully re‑rate the stock, while setbacks or regulatory delays can weigh heavily on the share price. Key considerations include cash runway, partnership or licensing deals, trial enrolment and data timelines. The stock can be volatile and suited to investors who accept higher risk for potential long‑term upside. This summary is educational and not personalised investment advice; it does not recommend buying or selling. Always assess suitability for your financial situation and consider seeking independent financial advice before making investment decisions.
Nuvation Bio (NUVB) Stock Forecast
Analyst price target, next 12 months
$11.50
+123.7% vs today's $5.14
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Nuvation Bio have a consensus 12-month target of $11.50, above the current price of $5.14.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Nuvation Bio's stock, expecting it to rise significantly in value.
Financial Health
NuVation Bio is generating strong revenue and cash flow, with a high profit margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Milestones Ahead
Upcoming trial readouts and regulatory steps can act as catalysts for valuation, though outcomes are uncertain and can drive volatility.
R&D‑Driven Progress
The company’s value depends on scientific progress and development execution; this can offer upside but also increases cash‑burn and execution risk.
Partnership Potential
Licensing or collaborations can provide funding and validation, but depend on successful data and mutual strategic fit; terms and timing vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
